Market Place
Sourcing Support
FDA Approves Roche`s Subcutaneous OCREVUS ZUNOVO With ENHANZE
13 Sep 2024 //
PR NEWSWIRE
Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US
13 Sep 2024 //
FDA
NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
12 Jul 2024 //
PHARMACEUTICAL-TECHNOLOGY
Genentech Inc Biologic Ocrelizumab Receives Approval in US
21 Jun 2024 //
FDA
Roche touts near-complete MS suppression for injectable Ocrevus
17 Apr 2024 //
FIERCE PHARMA
Genentech`s Biologic Ocrevus (ocrelizumab) Receives Approval in the U.S.
19 Jan 2024 //
FDA
Roche’s OCREVUS subcutaneous injection was non-inferior to intravenous infusion
11 Oct 2023 //
PRESS RELEASE
Genentech`s Biologic Ocrevus (ocrelizumab) Receives Approval in the U.S.
18 Aug 2023 //
FDA
Roche scores with subcutaneous version of MS drug Ocrevus
14 Jul 2023 //
FIERCE PHARMA
Early Treatment With Genentech’s Ocrevus Leads to Reduced Disease Progression
26 Oct 2022 //
BUSINESSWIRE
Roche to present new OCREVUS data in multiple sclerosis at ECTRIMS 2022
19 Oct 2022 //
GLOBENEWSWIRE
Genentech to Present Ocrevus Data in Multiple Sclerosis at ECTRIMS
19 Oct 2022 //
BUSINESSWIRE
Roche continues to salute the diversity of the MS community
24 Jun 2022 //
FIERCEPHARMA
New Data in Genentech’s Ocrevus (ocrelizumab) Show Benefit in Multiple Sclerosis
04 Apr 2022 //
BUSINESSWIRE
Genentech to Present Data Across Neuroscience Portfolio at 2022 AAN
24 Mar 2022 //
BUSINESSWIRE
Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early
13 Oct 2021 //
GLOBENEWSWIRE
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes
13 Oct 2021 //
GLOBENEWSWIRE
Genentech to Present New Data on Ocrevus and Enspryng
05 Oct 2021 //
BUSINESSWIRE
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG
04 Oct 2021 //
GLOBENEWSWIRE
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG
04 Oct 2021 //
GLOBENEWSWIRE
Roche’s Ocrevus shows significant benefit in early-stage MS patients
20 Apr 2021 //
PMLIVE
Roche touts Ocrevus benefits in treating MS early
17 Apr 2021 //
FIERCE PHARMA
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit
16 Apr 2021 //
BUSINESSWIRE
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit
16 Apr 2021 //
BUSINESSWIRE
Looking to cement its lead in packed MS market, Roche`s Ocrevus uncorks
16 Apr 2021 //
ENDPTS
FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion
14 Dec 2020 //
PRESS RELEASE
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion
14 Dec 2020 //
BUSINESSWIRE
Roche’s phase IIIb CASTING study of Ocrevus demonstrates effective treatment
13 Sep 2020 //
PHARMABIZ
Roche`s Ocrevus touts 2-year switching data in multiple sclerosis market
11 Sep 2020 //
FIERCE PHARMA
Genentech’s Ocrevus shows positive action in multiple sclerosis study
10 Sep 2020 //
SEEKINGALPHA
Roche to read out even more data on megablockbuster Ocrevus in MS
04 Sep 2020 //
ENDPTS
U.S. FDA extends review of Novartis` multiple sclerosis drug
04 Jun 2020 //
REUTERS
Novartis touts older cancer drug for MS in attack on Roche`s Ocrevus
27 May 2020 //
REUTERS
Genentech`s Ocrevus (Ocrelizumab) Receives Supplimental Approval In U.S
22 May 2020 //
FDA
Roche Gives Update On Ocrevus Studies
28 Apr 2020 //
PRESS RELEASE
US FDA and EMA accept applications for Roche’s OCREVUS shorter 2-hour infusion
20 Apr 2020 //
PRESS RELEASE
Ocrevus, Hemlibra offset Roche`s biosim loss
30 Jan 2020 //
FIERCE PHARMA
Genentech`s Ocrevus (ocrelizumab) Receives Supplimental Approval in U.S
13 Jan 2020 //
FDA
Roche aims its first Ocrevus commercials at millennials
30 Oct 2019 //
FIERCE PHARMA
Merck KGaA touts Mavenclad data as MS new drug race heats up
14 Sep 2019 //
FIERCE PHARMA
Roche`s Ocrevus, given early, cuts wheelchair risk by 42%: study
13 Sep 2019 //
FIERCE PHARMA
Novartis MS drug cuts relapse rate by half compared to Sanofi medicine
13 Sep 2019 //
REUTERS
Multi-study data confirm Ocrevus` efficacy in reducing disability progression MS
13 Sep 2019 //
PHARMAFILE
J&J`s head-to-head PhIII data promise drug launch into crowded MS market
13 Sep 2019 //
ENDPOINTSNEWS
Roche presents new Ocrevus biomarker data
11 Sep 2019 //
PHARMABIZ
Roche`s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
07 Sep 2019 //
FIERCEPHARMA
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
27 Aug 2019 //
BIOPHARMADIVE
WHO keeps key lung cancer drugs off its essential medicines list
10 Jul 2019 //
REUTERS
Novartis Gilenya staves off geric challengers? - for now.
26 Jun 2019 //
FIERCE PHARMA
Roche touts phase 2 Gazyva data in lupus patients
12 Jun 2019 //
FIERCE PHARMA
Roche snags first-in-class FDA nod for lymphoma drug Polivy
11 Jun 2019 //
FIERCE PHARMA
Roche`s Ocrevus discount wins over England`s cost watchdogs
10 May 2019 //
FIERCE PHARMA
Roche to present new OCREVUS (ocrelizumab) data analyses
08 May 2019 //
PRESS RELEASE
Roche and NHS England hail pricing deal on MS drug Ocrevus
08 May 2019 //
PMLIVE
Roche`s New Cancer, MS Drugs Pay Off With a Forecast Boost
18 Apr 2019 //
BLOOMBERGQUINT
Roche`s drugs, new and old, team up for major sales
17 Apr 2019 //
FIERCE PHARMA
Thanks to Ocrevus, Roche outgrows biosimilars attack to best quarter of 2018
31 Jan 2019 //
FIERCE PHARMA
